{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:19:05Z","timestamp":1763036345789},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2004,4,1]],"date-time":"2004-04-01T00:00:00Z","timestamp":1080777600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2004,4]]},"DOI":"10.1007\/bf02968301","type":"journal-article","created":{"date-parts":[[2008,10,8]],"date-time":"2008-10-08T03:03:43Z","timestamp":1223435023000},"page":"194-202","source":"Crossref","is-referenced-by-count":61,"title":["A phase II study of S-1 in patients with metastatic breast cancer \u2014 A Japanese trial by the S-1 cooperative study group, breast cancer working group"],"prefix":"10.1007","volume":"11","author":[{"given":"Toshiaki","family":"Saeki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigemitsu","family":"Takashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muneaki","family":"Sano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noboru","family":"Horikoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeto","family":"Miura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morihiko","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Aoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Ota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinzaburo","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuo","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF02968301_CR1","unstructured":"Piccart MJ, Awada A, Hamilton, A: Integration of new therapies into management of metastatic breast cancer: A focus on chemotherapy, treatment selection through use of molecular markers, and newly developed biologic therapies in late clinical development. 35th ASCO Educational Book, pp526\u2013539, 1999."},{"key":"BF02968301_CR2","first-page":"604","volume-title":"Breast Diseases","author":"IC Henderson","year":"1991","unstructured":"Henderson IC: Chemotherapy for metastatic disease. In: Harris JR, Hellmann S, Henderson IC, Kinne DW eds, Breast Diseases, 2nd ed, JB Lippincott Co, Philadelphia, pp604\u2013665, 1991.","edition":"2nd ed"},{"key":"BF02968301_CR3","first-page":"1","volume":"18","author":"EA Stadtmauer","year":"1999","unstructured":"Stadtmauer EA, O\u2019Neil A, Goldstein LJ, Crilley P, Mangan KF, Ingle JN, Lazarus HM, Erban J, Sickles C, Glick JH: Phase II randomized trial of high-dose chemotherapy (HDC) and stem cell support (SCT) shows no difference in overall survival or severe toxicity compared to maintenance chemotherapy with cyclophosphamide, methotorexate and 5-fluorouracil (CMF) for women with metastatic breast cancer who are responding to conventional induction chemotherapy: The Philadelphia intergroup study (PBT-1). 35thProc Am Soc Clin Oncol 18:#1a, 1999.","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF02968301_CR4","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/oxfordjournals.annonc.a010759","volume":"7","author":"S Regazzoni","year":"1996","unstructured":"Regazzoni S, Pesce G, Marini G, Cavalli F, Goldhirsch A: Low-dose continuous intravenous infusion of 5-fluorouracil for metastatic breast cancer.Annal Oncol 7:807\u2013813, 1996.","journal-title":"Annal Oncol"},{"key":"BF02968301_CR5","first-page":"301","volume":"16","author":"Meta-analysis group in Cancer","year":"1998","unstructured":"Meta-analysis group in Cancer: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectalcancer. J Clin Oncol 16:301\u2013308, 1998.","journal-title":"cancer. J Clin Oncol"},{"key":"BF02968301_CR6","first-page":"4399","volume":"41","author":"RT Chlebowski","year":"1981","unstructured":"Chlebowski RT, Weiner JM, Luce J, Hestorff R, Lang JE, Reynolds R, Godfrey T, Ryden VM, Bateman JR: Significance of relapse after adjuvant treatment with combination chemotherapy or 5-fluorouracil alone in high-risk breast cancer. A Western Cancer Study Group Project.Cancer Res 41:4399\u20134403, 1981.","journal-title":"Cancer Res"},{"key":"BF02968301_CR7","first-page":"100","volume-title":"New drugs in cancer chemotherapy","author":"JL Au","year":"1981","unstructured":"Au JL, Sadee W: The pharmacology of ftorafur (R, S-1-(tetrahydro2-furanyl)-5-fluorouracil). In: Carter SK, Sakurai Y, Umezawa H eds, New drugs in cancer chemotherapy, Springer-Verlag, New York, pp100\u2013114, 1981."},{"key":"BF02968301_CR8","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1200\/JCO.1983.1.2.107","volume":"1","author":"FJ Ansfield","year":"1983","unstructured":"Ansfield FJ, Kallas GJ, Singson JP: Phase I-II studies of oraltegafur (ftorafur).J Clin Oncol 1:107\u2013110, 1983.","journal-title":"J Clin Oncol"},{"key":"BF02968301_CR9","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S0959-8049(05)80426-5","volume":"29","author":"MJ Kajanti","year":"1993","unstructured":"Kajanti MJ, Pyrhonen S, Maiche AG: An oral tegafur in the treatment of metastatic breast cancer, a phase II study.EurJ Cancer 29A:863\u2013866, 1993.","journal-title":"EurJ Cancer"},{"key":"BF02968301_CR10","first-page":"333","volume":"22","author":"K Ota","year":"1988","unstructured":"Ota K, Taguchi T, Kimura K: Report on nationwide pooled data and cohort investigation in UFT phase II study.Cancer Chemother Pharmacol 22:333\u2013338, 1988.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF02968301_CR11","first-page":"2052","volume":"12","author":"T Taguchi","year":"1985","unstructured":"Taguchi T, Terasawa T, Abe O, Yoshida Y, Tominaga T, Ogawa NA: Comparative study between 5\u2019-DFUR and tegafur in recurrent breast cancer.Jpn J Cancer Chemoth 12:2052\u20132060, 1985 (in Japanese with English abstract).","journal-title":"Jpn J Cancer Chemoth"},{"key":"BF02968301_CR12","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0959-8049(98)00058-6","volume":"34","author":"M Miwa","year":"1998","unstructured":"Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.EurJ Cancer 34:1274\u20131281, 1998.","journal-title":"EurJ Cancer"},{"key":"BF02968301_CR13","doi-asserted-by":"crossref","first-page":"17102","DOI":"10.1016\/S0021-9258(18)41899-6","volume":"267","author":"ZH Lu","year":"1992","unstructured":"Lu ZH, Zhang R, Diasio RB: Purification and characterization of dihydropyrimidine dehydrogenase from human liver.J Biol Chem 267:17102\u201317109, 1992.","journal-title":"J Biol Chem"},{"issue":"Suppl. 3","key":"BF02968301_CR14","first-page":"17","volume":"13","author":"RB Diasio","year":"1999","unstructured":"Diasio RB: Clinical implications of dihydropyrimidine dehydrogenase inhibition.Oncology 13 (Suppl. 3): 17\u201321, 1999.","journal-title":"Oncology"},{"key":"BF02968301_CR15","first-page":"4004","volume":"53","author":"T Shirasaka","year":"1993","unstructured":"Shirasaka T, Shimamoto Y, Fukushima M: Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats.Cancer Res 53:4004\u20134009, 1993.","journal-title":"Cancer Res"},{"key":"BF02968301_CR16","first-page":"2602","volume":"56","author":"T Shirasaka","year":"1996","unstructured":"Shirasaka T, Nakano K, Takechi T, Satake H, Uchida J, Fujioka A, Saito H, Okabe H, Oyama K, Takeda S, Unemi N, Fukushima M: Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2, 4-dihydroxypyridine-lM potassium oxonate (S-l) against human colon carcinoma orthotopically implanted into nude rats.Cancer Res 56:2602\u20132606, 1996.","journal-title":"Cancer Res"},{"key":"BF02968301_CR17","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s002800050561","volume":"39","author":"T Takechi","year":"1997","unstructured":"Takechi T, Nakano K, Uchida J, Mita A, Toko K, Takeda S, Unemi N, Shirasaka T: Antitumor activity and low intestinal toxicity of S-l, a new formulation of oral tegafur, in experimental tumor models in rats.Cancer Chemother Pharmacol 39:205\u2013211, 1997.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF02968301_CR18","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s002800000123","volume":"46","author":"K Yoshisue","year":"2000","unstructured":"Yoshisue K, Hironaga K, Yamaguchi S, Yamamoto A, Nagayama S, Kawaguchi Y: Reduction of 5-fluo-rouracil (5-FU) gastrointestinal (GI) toxicity resulting from the protection of thymidylate synthase (TS) in GI tissue by repeated simultaneous administration of potassium oxonate (Oxo) in rats.Cancer Chemother Pharmacol 46:51\u201356, 2000.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF02968301_CR19","first-page":"2253","volume":"24","author":"T Taguchi","year":"1997","unstructured":"Taguchi T, Inuyama Y, Kanamaru R, Hasegawa K, Akazawa S, Niitani H, Furue H, Kurihara M, Ota K, Suga S, Ariyoshi Y, Takai S, Shimoyama T, Toge T, Takashima S, Sugimachi K, Hara Y, Fujita H, Kimura K, Saito T, Tsukagashi S, Nakao I: Phase I study of S-l.Jpn J Cancer Chemother 24:2253\u20132264, 1997 (in Japanese with English abstract).","journal-title":"Jpn J Cancer Chemother"},{"key":"BF02968301_CR20","volume-title":"WHO handbook for reporting results of cancer treatment WHO offset Publ.","author":"World Health Organization","year":"1979","unstructured":"World Health Organization: WHO handbook for reporting results of cancer treatment WHO offset Publ. No.48. Geneva, World health organization, 1979."},{"key":"BF02968301_CR21","first-page":"101","volume":"28","author":"Japan Society for Cancer Therapy","year":"1993","unstructured":"Japan Society for Cancer Therapy: Criteria for the evaluation of the clinical effects of solid cancer chemotherapy.JJpn Soc Cancer Ther 28:101\u2013130, 1993.","journal-title":"JJpn Soc Cancer Ther"},{"key":"BF02968301_CR22","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P: Nonparametric estimation from incomplete observations.J Am Stat Assoc 53:457\u2013481, 1958.","journal-title":"J Am Stat Assoc"},{"key":"BF02968301_CR23","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/bjc.1998.12","volume":"77","author":"M Arellano","year":"1988","unstructured":"Arellano M, Malet-Martino M, Martino R, Gires P: The anti-cancer drug 5-fluorouracil is metabolized by the isolated perfused rat liver and in rats into highly toxic fluoroacetate.Br J Cancer 77:79\u201386, 1988.","journal-title":"Br J Cancer"},{"key":"BF02968301_CR24","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/BF00662639","volume":"81","author":"R Okeda","year":"1990","unstructured":"Okeda R, Shibutani M, Matsuo T, Kuroiwa T, Shimokawa R, Tajima T: Experimental neurotoxicity of 5-fluorouracil and its derivatives is due to poisoning by the monofluorinated organic metabolites, monofluoroacetatic acid and \u03b1-fluoro-\u03b2-alanine.Acta Neuropathol 81:66\u201373, 1990.","journal-title":"Acta Neuropathol"},{"key":"BF02968301_CR25","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1200\/JCO.1994.12.11.2296","volume":"12","author":"R Pazdur","year":"1994","unstructured":"Pazdur R, Lassere Y, Rhodes V, Ajani JA, Sugarman SM, Part YZ, Jones DV Jr, Markowitz AB, Abbruzzese JL, Bready B, Levin B: Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma.J Clin Oncol 12:2296\u20132300, 1994.","journal-title":"J Clin Oncol"},{"issue":"Suppl. 1","key":"BF02968301_CR26","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1159\/000227737","volume":"54","author":"AH Villalon","year":"1997","unstructured":"Villalon AH, De Guzman LM, Samson MC, Guancia AA, Fernando GY, Romana IB: A comparative, randomized trial of UFT and 5-fluorouracil in combination with cyclophosphamide and doxorubicin in the treatment of advanced breast cancer patients at the Philippines general hospital.Oncology 54 (Suppl. 1):2\u20136, 1997.","journal-title":"Oncology"},{"key":"BF02968301_CR27","first-page":"2085","volume":"4","author":"DH Ho","year":"1998","unstructured":"Ho DH, Pazdur R, Covington W, Brown N, Huo YY, Lassere Y, Kuritani J: Comparison of 5-Fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus Nl-(2\u2019-tetrahydrofuryl)-5-fluorouracil.Clin Cancer Res 4:2085\u20132088, 1998.","journal-title":"Clin Cancer Res"},{"key":"BF02968301_CR28","first-page":"2002","volume":"5","author":"K Hirata","year":"1999","unstructured":"Hirata K, Horikoshi N, Aiba K, Okazaki M, Denno R, Sasaki K, Nakano Y, Ishizuka H, Shirasaka T: Pharmacokinetic study of S-l, a novel oral fluorouracil antitumor drug.Clin Cancer Res 5:2002\u20132005, 1999.","journal-title":"Clin Cancer Res"},{"key":"BF02968301_CR29","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/S0959-8049(98)00211-1","volume":"34","author":"Y Sakata","year":"1998","unstructured":"Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T: Late phase II study of novel oral fluoropyrimidine anticancer drug S-l (IM tega-fur-0.4M gimestat-lM otastat potassium) in advanced gastric cancer patients.Eur J Cancer 34:1715\u20131720, 1998.","journal-title":"Eur J Cancer"},{"key":"BF02968301_CR30","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1200\/JCO.1999.17.2.485","volume":"17","author":"JL Blum","year":"1999","unstructured":"Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown CS, Griffin T: Multicenter Phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer.J Clin Oncol 17:485\u2013493, 1999.","journal-title":"J Clin Oncol"},{"key":"BF02968301_CR31","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1002\/1097-0142(20011001)92:7<1759::AID-CNCR1691>3.0.CO;2-A","volume":"92","author":"JL Blum","year":"2001","unstructured":"Blum JL, Dieras V, Russo PML, Horton J, Rutman O, Buzdar A, Osterwalder B: Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients.Cancer 92:1759\u20131768, 2001.","journal-title":"Cancer"},{"key":"BF02968301_CR32","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1016\/S0959-8049(01)00309-4","volume":"37","author":"CH Smorenburg","year":"2001","unstructured":"Smorenburg CH, Sparreboom A, Bontenbal M, Ver-weij J: Combination chemotherapy of the taxanes and antimetabolites: its use and limitations.Eur J Cancer 37:2310\u20132323, 2001.","journal-title":"Eur J Cancer"},{"key":"BF02968301_CR33","first-page":"685","volume":"58","author":"T Ishikawa","year":"1998","unstructured":"Ishikawa T, Sekiguchi F, Fukase Y, Sawada N, Ishit-suka H: Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts.Cancer Res 58:685\u2013690, 1998.","journal-title":"Cancer Res"},{"key":"BF02968301_CR34","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1200\/JCO.1997.15.1.110","volume":"15","author":"G Liu","year":"1997","unstructured":"Liu G, Franssen E, Fitch MI, Warner E: Patient preferences for oral versus intravenous palliative chemohtherapy.J Clin Oncol 15:110\u2013115, 1997.","journal-title":"J Clin Oncol"},{"key":"BF02968301_CR35","doi-asserted-by":"crossref","first-page":"11064","DOI":"10.1073\/pnas.90.23.11064","volume":"90","author":"DP Baccanari","year":"1993","unstructured":"Baccanari DP, Davis ST, Knick VC, Spector T: 5-Ethynyluracil (776C85): A potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluo-rouracil.Proc Natl Acad Sei USA 90:11064\u201311068, 1993","journal-title":"Proc Natl Acad Sei USA"},{"key":"BF02968301_CR36","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1200\/JCO.1996.14.12.3085","volume":"14","author":"SD Baker","year":"1996","unstructured":"Baker SD, Khor SP, Adjei AA, Doucette M, Spector T, Donehower RC, Grochow LB, Sartorius SE, Noe DA, Hohneker JA, Rowinsky EK: Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase.J Clin Oncol 14:3085\u20133096, 1996.","journal-title":"J Clin Oncol"},{"key":"BF02968301_CR37","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1200\/JCO.2002.20.4.987","volume":"20","author":"E Rivera","year":"2002","unstructured":"Rivera E, Sutton L, Colwell B, Graham M, Frye D, Somerville M, Conklin HS, McGuirt C, Levin J, Horto-bagyi GN: Multicenter phase II study of a 28-day regimen of orally administered eniluracil and fluorouracil in the treatment of patients with anthracycline- and taxane-resistant advanced breast cancer.J Clin Oncol 20:987\u2013993, 2002.","journal-title":"J Clin Oncol"},{"key":"BF02968301_CR38","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1200\/JCO.2002.20.4.894","volume":"20","author":"RB Diasio","year":"2002","unstructured":"Diasio RB: An evolving role for oral fluoropyrimidine drugs.J Clin Oncol 20:894\u2013896, 2002.","journal-title":"J Clin Oncol"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02968301.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF02968301\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02968301","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,18]],"date-time":"2021-09-18T00:52:24Z","timestamp":1631926344000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF02968301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,4]]}},"alternative-id":["BF02968301"],"URL":"https:\/\/doi.org\/10.1007\/bf02968301","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,4]]}}}